Gastrointestinal conditions affect millions across the UK, yet research in the field has often been fragmented, slow, or under-resourced
The Phase 1 single and multiple ascending dose study is set to begin dosing in early Q1 2026
Aspect has acquired rights to Novo Nordisk’s stem cell-derived islet cell and hypoimmune cell engineering technologies
The study evaluated patients with stage III/IV melanoma after complete tumor resection
The new investment will fuel expansion of Avalon's Diagnostic Intelligence capabilities
The collaboration aims to accelerate the delivery of challenging DNA motifs with speed, precision, and reliability
Myqorzo, a selective small-molecule cardiac myosin inhibitor, is designed to improve functional capacity and relieve symptoms in oHCM
DNA nanorobots—tiny, self-assembling machines capable of detecting diseases in blood samples within 2–4 hours
The company recorded revenue of Rs. 1,065 crore in the third quarter of FY26
The randomized, double-blind, placebo-controlled Phase 2b VITAL trial enrolled 91 patients with newly diagnosed Stage IIIb–IV epithelial ovarian cancer
Subscribe To Our Newsletter & Stay Updated
